Trial Profile

Pharmacodynamic Biomarkers to Support Biosimilar Development: Clinical Study 2: PCSK9 Inhibitors - Alirocumab and Evolocumab

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 24 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Alirocumab (Primary) ; Evolocumab (Primary)
Indications Atherosclerosis; Coronary artery disease; Coronary disorders; Dyslipidaemias; Hypercholesterolaemia; Hyperlipidaemia; Hyperlipoproteinaemia type IIa; Myocardial infarction; Stroke
Focus Pharmacodynamics; Pharmacokinetics

Most Recent Events

25 Oct 2022 Results analyzing use of Pharmacodynamic Biomarkers to Support Biosimilar Development, published in the Clinical Pharmacology and Therapeutics
30 Apr 2021 Status changed from recruiting to completed.
08 Jan 2021 Planned End Date changed from 1 Feb 2021 to 1 Apr 2021.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com